A retrospective cohort of 72 biopsy-confirmed patients with monoclonal immunoglobulin deposition disease was analyzed by the study team. Patients were allocated by first-line therapy to a bortezomib/dexamethasone (BD) group (n = 37) or a thalidomide/dexamethasone (TD) group (n = 35). The investigators reported that baseline characteristics were comparable between the two groups. Evaluable-patient analyses showed a deeper hematological response with BD: the rate of hematological complete response/very good partial response reached 63% in the BD cohort versus 46% with TD. Renal responses mirrored the hematological data; renal complete response/very good partial response rates were 57% for BD compared with 32% for TD. These differences were emphasized by the authors as clinically meaningful in the cohort they reviewed.
The authors reported better renal survival at five years in patients receiving bortezomib/dexamethasone: 73% versus 51% for the thalidomide/dexamethasone group. Overall survival at five years showed a favorable trend for BD as well (85% vs. 64%), although the abstract presents this as a trend rather than a definitive statistical claim. When the BD group was subdivided, the BD-only subgroup (those who did not proceed to transplant) demonstrated higher complete response rates and favorable survival trends compared with TD. The study team did not provide full survival curve data or granular time-to-event statistics within the abstract text; those details may appear in the full article.
Eight patients in the BD cohort received autologous stem cell transplantation (ASCT) following induction. The authors observed an increase in hematological complete response from 25% after induction to 75% after transplant in this small ASCT subgroup. The contrast is stark: ASCT appeared to deepen hematological remission in transplant-eligible patients within this dataset. The abstract does not describe conditioning regimens, timing between induction and transplant, or transplant-related morbidity and mortality; those procedural details were not reported in the abstract.
The study team ran multivariate analyses to identify independent predictors of renal survival. They reported three protective factors: chronic kidney disease (CKD) stage ≤3 at baseline, achieving hematological complete response/very good partial response, and receiving the bortezomib/dexamethasone regimen. The investigators interpreted these findings as evidence that both baseline renal function and depth of hematological remission influence renal outcomes, and that BD therapy independently associated with improved renal preservation. The abstract does not present the full model coefficients, hazard ratios, or confidence intervals; such statistical detail would require access to the full text.
Safety data, summarized in the abstract, revealed differing toxicity profiles. Neurotoxicity occurred in 19% of patients treated with BD and in 29% of patients treated with TD. The authors noted that anemia and peripheral edema were more frequent in the TD group. Importantly, the cohort experienced no treatment-related deaths according to the abstract. The report does not specify neurotoxicity grading, management strategies, or whether dose modifications occurred; these specific tolerability and management data were not reported in the abstract.
This is a retrospective comparative study covering patients diagnosed between 2005 and 2025. Retrospective design carries inherent limitations for causal inference, and the abstract does not provide full methodological detail such as dosing regimens for either BD or TD, exact follow-up duration for each patient, or the complete set of statistical measures behind reported comparisons. The authors recommend bortezomib/dexamethasone as first-line therapy for patients with monoclonal immunoglobulin deposition disease, advocating BD followed by ASCT for transplant-eligible patients and BD alone for those who are ineligible. Remaining, specific unanswered clinical questions documented in the abstract include the absence of detailed dosing and schedule data and limited procedural detail for ASCT; the abstract also does not supply comprehensive multivariate statistics or adverse-event grading. These gaps are noted in the abstract and would need the full paper for verification and extended interpretation.